8.62
price down icon7.01%   -0.65
after-market After Hours: 8.60 -0.02 -0.23%
loading
Anavex Life Sciences Corporation stock is traded at $8.62, with a volume of 2.29M. It is down -7.01% in the last 24 hours and down -8.00% over the past month. Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
See More
Previous Close:
$9.27
Open:
$9.29
24h Volume:
2.29M
Relative Volume:
2.00
Market Cap:
$740.40M
Revenue:
-
Net Income/Loss:
$-48.17M
P/E Ratio:
-15.12
EPS:
-0.57
Net Cash Flow:
$-37.10M
1W Performance:
-10.30%
1M Performance:
-8.00%
6M Performance:
-2.71%
1Y Performance:
+60.22%
1-Day Range:
Value
$8.34
$9.29
1-Week Range:
Value
$8.34
$10.38
52-Week Range:
Value
$5.22
$14.44

Anavex Life Sciences Corporation Stock (AVXL) Company Profile

Name
Name
Anavex Life Sciences Corporation
Name
Phone
844-689-3939
Name
Address
630 5TH AVENUE, NEW YORK
Name
Employee
2
Name
Twitter
@anavexlifesci
Name
Next Earnings Date
2024-12-31
Name
Latest SEC Filings
Name
AVXL's Discussions on Twitter

Compare AVXL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AVXL
Anavex Life Sciences Corporation
8.62 796.24M 0 -48.17M -37.10M -0.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-06-22 Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-23-22 Initiated Berenberg Buy
Sep-23-21 Initiated BTIG Research Buy
Dec-16-20 Reiterated H.C. Wainwright Buy
Sep-28-20 Initiated Ladenburg Thalmann Buy
Feb-27-20 Initiated Cantor Fitzgerald Overweight
Jun-18-19 Initiated Janney Buy
May-16-18 Resumed Maxim Group Buy
Mar-08-18 Initiated ROTH Capital Buy
Feb-13-18 Reiterated Maxim Group Buy
Sep-29-17 Resumed Noble Financial Buy
Feb-07-17 Initiated Noble Financial Buy
Mar-29-16 Initiated FBR Capital Outperform
View All

Anavex Life Sciences Corporation Stock (AVXL) Latest News

pulisher
11:57 AM

How strong is Anavex Life Sciences Corp. stock revenue growthWeekly Investment Recap & Weekly High Conviction Ideas - newser.com

11:57 AM
pulisher
10:58 AM

Detecting price anomalies in Anavex Life Sciences Corp. with AIJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - newser.com

10:58 AM
pulisher
10:32 AM

Real time breakdown of Anavex Life Sciences Corp. stock performanceMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com

10:32 AM
pulisher
08:31 AM

Can trapped investors hope for a rebound in Anavex Life Sciences Corp.July 2025 Sentiment & Long-Term Safe Investment Plans - newser.com

08:31 AM
pulisher
07:57 AM

How Anavex Life Sciences Corp. stock valuations compare to rivalsJuly 2025 Update & AI Powered Market Entry Strategies - newser.com

07:57 AM
pulisher
Oct 12, 2025

Heatmap analysis for Anavex Life Sciences Corp. and competitorsWeekly Stock Summary & Safe Entry Zone Identification - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ - The Manila Times

Oct 10, 2025
pulisher
Oct 10, 2025

Anavex Life Sciences Corp. Announces Oral Presentation on Alzheimer's Disease Care at Alzheimer Europe Conference - Quiver Quantitative

Oct 10, 2025
pulisher
Oct 10, 2025

Oral Blarcamesine Presented at 35th Alzheimer Europe — Anavex Highlights ANAVEX®2-73-AD-004 IIb/III - Stock Titan

Oct 10, 2025
pulisher
Oct 10, 2025

Will Anavex Life Sciences Corp. (12X1) stock keep high P E multiplesJuly 2025 Analyst Calls & Growth Focused Investment Plans - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Is Anavex Life Sciences Corp. (12X1) stock testing key supportWeekly Trade Report & Community Verified Trade Alerts - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Anavex Life Sciences (NASDAQ:AVXL) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat

Oct 08, 2025
pulisher
Oct 07, 2025

Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

HC Wainwright & Co. Reiterates Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq

Oct 07, 2025
pulisher
Oct 07, 2025

Anavex Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com

Oct 07, 2025
pulisher
Oct 06, 2025

How Anavex Life Sciences Corp. stock reacts to global recession fearsBreakout Watch & Low Drawdown Momentum Ideas - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Long term hold vs stop loss in Anavex Life Sciences Corp.Analyst Downgrade & Community Consensus Stock Picks - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Tools to monitor Anavex Life Sciences Corp. recovery probabilityEarnings Risk Report & Advanced Technical Signal Analysis - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Anavex Life Sciences (NASDAQ:AVXL) Trading Up 8.7%Should You Buy? - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Anavex Life Sciences (Nasdaq:AVXL) Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia - Kalkine Media

Oct 03, 2025
pulisher
Oct 02, 2025

D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq

Oct 02, 2025
pulisher
Oct 02, 2025

Is Anavex Life Sciences Corp a good long term investmentBollinger Bands Signals & Free Phenomenal Capital Appreciation - earlytimes.in

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia - Seeking Alpha

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences (NASDAQ:AVXL) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences (AVXL): Analyst Reaffirms "Buy" Rating | AV - GuruFocus

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update - Stocktwits

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences (AVXL) Shares Rise on Positive Trial Result - GuruFocus

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia Clinical Study Achieving Safety and Tolerability Endpoints - Quiver Quantitative

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program - The Manila Times

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences stock rises after positive schizophrenia drug trial - Investing.com

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Develops Once-Daily Tablet for ANAVEX3-71 in Phase 1b Trial | AVXL Stock News - Stock Titan

Oct 02, 2025
pulisher
Oct 02, 2025

Novel Schizophrenia Drug ANAVEX3-71 Shows Promise: Safe Profile and Reduced Brain Inflammation Markers - Stock Titan

Oct 02, 2025
pulisher
Oct 02, 2025

Anavex Life Sciences (NASDAQ:AVXL) Receives “Buy” Rating from D. Boral Capital - Defense World

Oct 02, 2025
pulisher
Oct 01, 2025

Alzheimer’s Disease Market: Epidemiology, Therapies, and Key Players | Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuti - Barchart.com

Oct 01, 2025
pulisher
Oct 01, 2025

Anavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from D. Boral Capital - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

Alzheimer's Disease Market: Epidemiology, Therapies, And Key Players Anavex Life Sciences Corp., Taurx Therapeutics Ltd, Biovie Inc., Aribio Co., Ltd., Novo Nordisk A/S, Agenebio, Neurim Pharmaceuti - Menafn.com

Oct 01, 2025
pulisher
Oct 01, 2025

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial - markets.businessinsider.com

Oct 01, 2025
pulisher
Sep 30, 2025

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial - Investing News Network

Sep 30, 2025
pulisher
Sep 30, 2025

Anavex Life Sciences Announces Publication of Oral - GlobeNewswire

Sep 30, 2025
pulisher
Sep 30, 2025

70% Success Rate: Anavex's Once-Daily Oral Alzheimer's Drug Shows Breakthrough Results in Late-Stage Trial - Stock Titan

Sep 30, 2025
pulisher
Sep 30, 2025

Why millennials buy Anavex Life Sciences Corp. (12X1) stockJuly 2025 PostEarnings & Daily Price Action Insights - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

How to recover losses in Anavex Life Sciences Corp. stockJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Real time pattern detection on Anavex Life Sciences Corp. stockMarket Volume Summary & Target Return Focused Stock Picks - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

What drives PRCT stock priceMarket Sentiment Shifts & These 3 Stocks Could Change Your Portfolio - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

What drives Anavex Life Sciences Corp stock priceOptions Trading Strategies & Minimal Capital Growth Plans - earlytimes.in

Sep 28, 2025
pulisher
Sep 26, 2025

What analysts say about Anavex Life Sciences Corp stockEquity Performance Review & Stocks With 200% Upside Potential - Early Times

Sep 26, 2025
pulisher
Sep 26, 2025

How Anavex Life Sciences Corp. (12X1) stock trades pre earningsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com

Sep 26, 2025
pulisher
Sep 24, 2025

H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target - Insider Monkey

Sep 24, 2025
pulisher
Sep 22, 2025

Anavex Life Sciences Corp. $AVXL Shares Sold by Goldman Sachs Group Inc. - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Published on: 2025-09-22 05:58:42 - newser.com

Sep 22, 2025

Anavex Life Sciences Corporation Stock (AVXL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Anavex Life Sciences Corporation Stock (AVXL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Thomas Steffen
Director
Jun 05 '25
Option Exercise
1.76
50,000
88,000
55,000
MISSLING CHRISTOPHER U
President and CEO
Mar 24 '25
Option Exercise
0.92
500,000
460,000
1,750,210
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):